User login
Key clinical point: Treatment with anaerobically cultivated human intestinal microbiota (ACHIM) suspension or donor fecal microbiota transplantation (donor-FMT) but not placebo changed gut microbiota profiles in patients with irritable bowel syndrome (IBS) to those measured in healthy control individuals along with significant changes in bacterial strain signal.
Major finding: Patients receiving donor-FMT vs placebo had more significant bacterial strain signals for Actinobacteria spp. and Bifidobacteria spp., whereas those receiving ACHIM or donor-FMT vs placebo had more significant signals for Alistipes onderdonkii (all P < .05). After receiving ACHIM suspension or donor-FMT, but not placebo, the bacterial signal in patients resembled more that in healthy controls. No post-transplant complications were reported.
Study details: The data come from a randomized controlled study including 43 patients with IBS-D who received ACHIM suspension (n = 17), donor-FMT (n = 11), or placebo (patient’s own feces; n = 15).
Disclosures: This study was funded by Helse Vest, Norway. The authors declared no conflicts of interest.
Source: Mazzawi T et al. The effect of anaerobically cultivated human intestinal microbiota compared to fecal microbiota transplantation on gut microbiota profile and symptoms of irritable bowel syndrome, a double-blind placebo-controlled study. Microorganisms. 2022;10(9):1819 (Sep 11). Doi: 10.3390/microorganisms10091819
Key clinical point: Treatment with anaerobically cultivated human intestinal microbiota (ACHIM) suspension or donor fecal microbiota transplantation (donor-FMT) but not placebo changed gut microbiota profiles in patients with irritable bowel syndrome (IBS) to those measured in healthy control individuals along with significant changes in bacterial strain signal.
Major finding: Patients receiving donor-FMT vs placebo had more significant bacterial strain signals for Actinobacteria spp. and Bifidobacteria spp., whereas those receiving ACHIM or donor-FMT vs placebo had more significant signals for Alistipes onderdonkii (all P < .05). After receiving ACHIM suspension or donor-FMT, but not placebo, the bacterial signal in patients resembled more that in healthy controls. No post-transplant complications were reported.
Study details: The data come from a randomized controlled study including 43 patients with IBS-D who received ACHIM suspension (n = 17), donor-FMT (n = 11), or placebo (patient’s own feces; n = 15).
Disclosures: This study was funded by Helse Vest, Norway. The authors declared no conflicts of interest.
Source: Mazzawi T et al. The effect of anaerobically cultivated human intestinal microbiota compared to fecal microbiota transplantation on gut microbiota profile and symptoms of irritable bowel syndrome, a double-blind placebo-controlled study. Microorganisms. 2022;10(9):1819 (Sep 11). Doi: 10.3390/microorganisms10091819
Key clinical point: Treatment with anaerobically cultivated human intestinal microbiota (ACHIM) suspension or donor fecal microbiota transplantation (donor-FMT) but not placebo changed gut microbiota profiles in patients with irritable bowel syndrome (IBS) to those measured in healthy control individuals along with significant changes in bacterial strain signal.
Major finding: Patients receiving donor-FMT vs placebo had more significant bacterial strain signals for Actinobacteria spp. and Bifidobacteria spp., whereas those receiving ACHIM or donor-FMT vs placebo had more significant signals for Alistipes onderdonkii (all P < .05). After receiving ACHIM suspension or donor-FMT, but not placebo, the bacterial signal in patients resembled more that in healthy controls. No post-transplant complications were reported.
Study details: The data come from a randomized controlled study including 43 patients with IBS-D who received ACHIM suspension (n = 17), donor-FMT (n = 11), or placebo (patient’s own feces; n = 15).
Disclosures: This study was funded by Helse Vest, Norway. The authors declared no conflicts of interest.
Source: Mazzawi T et al. The effect of anaerobically cultivated human intestinal microbiota compared to fecal microbiota transplantation on gut microbiota profile and symptoms of irritable bowel syndrome, a double-blind placebo-controlled study. Microorganisms. 2022;10(9):1819 (Sep 11). Doi: 10.3390/microorganisms10091819